Call of the Innovative Medicines Initiative IMI2

26 de December de 2018

The updated texts of the topics of the next edition of the Innovative Medicines Initiative (IMI2), corresponding to the recently published Work Program of 2019 (more info, HERE), have already been published.

It is a call in two phases. Phase 1 will open prospectively on January 22, 2019. The topics considered are the following:

  • Optimising future obesity treatment.
  • Open access chemogenomics library and chemical probes for the druggable genome.
  • Intelligent prediction and identification of environmental risks posed by human medicinal products.

The text of the topics can be found at the following link: 

Likewise, registration has already been opened for the webinars of this call, which will take place between 23 and 31 January 2019, being the registration free but mandatory. A seminar will be held for each topic, in which the coordinator of the topic by EFPIA will make a presentation of it, being open to the questions of the attendees. There will also be a specific webinar on rules and procedures of IMI and another dedicated to the opportunities of participation of SMEs in this call.

You can find all the information and access the registry at the following link:

Potential future topics

The list of topics that are being considered for future calls has been published. The discussion of these topics is still in an initial state, so they can change considerably, even disappear topics or include others. The topics under consideration are the following:

  • Neurodegeneration / neuroscience: digital transformation of clinical trial endpoints in pain; placebo effect in pain; psychiatric ratings using intermediate stratified markers.
  • Immunology: Psoriatic arthritis.
  • Infection control including vaccines: new topic(s) under the AMR accelerator platform.
  • Translational safety: dosing in specific populations; digital pathology.
  • Big data, digital health, clinical trials and regulatory research: ROADMAP 2 – need and opportunity for public-private collaborative research to continue the RoadMap efforts; independent observatories of health outcomes for patients being the guardians of health data; e-product information – leveraging digital technology to drive the correct use and understanding of medicines: a user-centric approach to adherence and risk minimization.
  • Oncology: patient-reported outcomes and quality of life endpoints.
  • Facilitating the translation of advanced therapies to patients in Europe: accelerating research and development of Advanced Therapies; ATMP Patient Registries Outcomes Data and Evidence; CAR-Ts; Innovative Manufacturing of Advanced Therapeutic Medicinal Products, ATMPs.
  • Other enablers of research topics: handling of biologic drug products.

More information can be found in this document (link), which is also included in the Future Topics page